Berkshire’s Late-2025 Apple Stake Trim, OxyChem $9.7B Buy Highlight Abel’s Strategy
Berkshire Hathaway trimmed its Apple stake during late 2025 while building positions in The New York Times, Chevron and OxyChem, reflecting CEO Greg Abel’s selective capital deployment. Abel’s first annual letter, due with Berkshire’s 2025 results today, may outline plans for buybacks or acquisitions that could alter future Apple demand.
1. 2025 Annual Report and Abel’s First Letter
Berkshire Hathaway is set to publish its 2025 annual report today, featuring CEO Greg Abel’s inaugural letter to shareholders. The letter is expected to detail the new management’s capital allocation priorities in an environment of elevated interest rates.
2. Apple Stake Reduction
In late 2025, Berkshire reduced its holdings in Apple as part of a broader portfolio shuffle. The move underscores management’s cautious stance on large equity positions following Warren Buffett’s departure.
3. Other Investments and Cash Strategy
Alongside trimming tech stakes, Berkshire acquired about 5.07 million New York Times shares and closed a $9.7 billion OxyChem purchase. The conglomerate still holds over $380 billion in cash, signaling readiness for opportunistic deals.
4. Potential Impact on Apple Shares
Berkshire’s sale of Apple shares could modestly influence market supply and investor sentiment. Abel’s commentary on future buybacks or acquisitions may also guide perceptions of Apple’s demand outlook.